Alkasolve

Quick links to important sections

Alkasolve

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alkasolve

Alkasolve: Defining the Medicine and Its Purpose

Property Description
Active ingredient Magnesium Trisilicate (INN)
Form Chewable Tablet, Oral Suspension
Pharmacological Class Antacid, Adsorbent
Typical Use Symptomatic relief of heartburn and indigestion
Origin Synthetic Mineral Compound

Alkasolve is an over-the-counter (OTC) medication categorized as an antacid and adsorbent. Its primary function is the rapid, non-systemic neutralization of excess hydrochloric acid in the stomach and esophagus. This neutralizing action provides quick symptomatic relief from temporary digestive discomforts, such as heartburn, sour stomach, and indigestion caused by gastric hyperacidity.

The speed of action makes it a suitable first-line treatment for occasional acid-related distress. The general therapeutic purpose of this class of medicine is to quickly restore a more neutral pH balance in the upper gastrointestinal tract.

Understanding Alkasolve's Composition and Differentiation

The principal component that grants Alkasolve its antacid properties is the active ingredient, Magnesium Trisilicate (INN). This substance is an inorganic synthetic compound, manufactured to strict pharmaceutical standards, and is not derived directly from a botanical source.

Magnesium Trisilicate is recognized for its unique ability to form a protective gel-like layer on the gastric lining, which offers a potentially prolonged soothing effect in addition to its immediate acid-neutralizing capacity. This formulation is typically available for oral use in forms designed for efficient delivery to the stomach, such as chewable tablets or suspensions.

What side effects are possible with Alkasolve?

Possible Side Effects and Safety Information

The safety profile of Alkasolve (Potassium Citrate) is primarily structured around effects on the gastrointestinal system and the potential for severe metabolic imbalance, as documented in official government regulatory documents.

Documented Adverse Reactions

Adverse reactions associated with Alkasolve are classified by the organ systems affected. Gastrointestinal disturbances are noted as the most frequent occurrences. The most common effects include:

  • Gastrointestinal Disorders: Abdominal discomfort, nausea, vomiting, diarrhea, and loose stools.

Serious Adverse Reactions

The regulatory safety profile highlights risks that may be serious and require immediate attention. These include:

  • Severe Hyperkalemia: A potentially life-threatening elevation of serum potassium levels, classified under Metabolism and Nutrition Disorders.
  • Gastrointestinal Lesions: A risk of severe injury to the digestive tract, such as ulceration, obstruction, or perforation, particularly in susceptible individuals.

Safety Considerations and Restrictions

Official prescribing information outlines specific patient populations and conditions where the medicine is contraindicated due to heightened risk. These include individuals with:

  • Severe Renal Impairment: Due to the inability to properly excrete potassium, increasing the risk of hyperkalemia.
  • Active Urinary Tract Infection: Which may be exacerbated by the medication's effect on urinary pH.
  • Conditions Causing Slow Gastrointestinal Transit: Such as GI obstruction or esophageal compression, which increases the risk of gastrointestinal lesions.

Population and Timing-Related Safety Notes

Safety data specifies caution for older adults and patients with pre-existing cardiac disease due to their increased susceptibility to the serious effects of hyperkalemia. Furthermore, gastrointestinal symptoms are sometimes managed by administering the dose immediately after a full meal, as noted in the regulatory text.

Overdose and Emergency Response

The official regulatory documentation states that an overdose of Alkasolve is primarily defined by the development of Hyperkalemia, which is an elevated concentration of potassium in the bloodstream. This condition may be initially asymptomatic, but can present with clinical manifestations such as listlessness, general muscular weakness, mental confusion, or tingling of the extremities. Large acute overexposures may also result in metabolic Alkalosis.

The most severe documented outcome of overdose is the potential for fatal cardiac arrhythmias or cardiac arrest, a risk reflected by specific Electrocardiographic (ECG) changes noted in the official prescribing information. Given this hazard, regulatory guidance mandates that individuals seek emergency medical attention immediately if any suspected overdose symptoms occur. Furthermore, the medication must be discontinued immediately if severe vomiting, persistent abdominal pain, or evidence of gastrointestinal bleeding is observed.

The danger of developing life-threatening hyperkalemia is greater in specific patient populations, particularly those with severe renal impairment or those concurrently taking certain medications like potassium-sparing diuretics or ACE inhibitors. Treatment is focused on the immediate management of hyperkalemia, requiring continuous cardiac monitoring and supportive procedures such as the use of ion-exchange resins or potential dialysis. Official instructions describe the need for careful attention to acid-base balance and serum electrolyte monitoring.

Therapeutic Uses of Alkasolve

Quick Facts

  • Main Use: Management of specific kidney stone conditions.
  • Therapeutic Action: Contributes to alkalinizing the urine.
  • Related Conditions: Renal tubular acidosis (RTA), hypocitraturic calcium oxalate nephrolithiasis.
  • Other Benefit: Used for the management of uric acid lithiasis.

What Alkasolve Treats: Main Uses and Benefits

Alkasolve, which contains potassium citrate, is a therapeutic option used for the management of specific conditions that affect the urinary tract and kidneys. This medication is indicated to assist in correcting certain metabolic imbalances related to stone formation.

Its approved applications focus on the management of several types of kidney stone conditions. These include treating renal tubular acidosis (RTA) in patients who also have calcium stones. Additionally, it is used for the management of hypocitraturic calcium oxalate nephrolithiasis, which involves low levels of citrate in the urine associated with calcium oxalate stones. The medication is also utilized to help manage uric acid lithiasis, with or without the presence of calcium stones.

The mechanism of action involves functioning as a systemic alkalinizer, which aids in making the urine less acidic. This change in urinary pH helps reduce the susceptibility of the urine to the formation of crystals and stones from certain salts. Patients should discuss their full treatment plan and monitoring schedule with a healthcare professional.

Eligibility and Restrictions for Use

Alkasolve (Potassium Citrate) eligibility is determined by patient physiological status and coexisting medical conditions, as strictly defined in official regulatory documents.

Eligibility Scope

Classification Population/Condition Restriction Type
Contraindicated Chronic renal failure, uncontrolled diabetes mellitus, or severe myocardial damage. High risk of hyperkalemia
Contraindicated Peptic ulcer disease, GI obstruction, or delayed gastric emptying. Risk of gastrointestinal lesions
Contraindicated Active urinary tract infection, Addison's disease, or use with potassium-sparing diuretics. Comorbidity or drug interaction risk
Not Established Pediatric patients (children and adolescents). Insufficient safety and effectiveness data
Conditional Use Pregnancy and nursing mothers. Use only if clearly needed and benefit justifies potential risk

Official Eligibility Statements

  • The medicine is contraindicated in patients with conditions that predispose them to hyperkalemia, which is a dangerously high blood potassium level.
  • Use is also contraindicated if there is any condition that causes an arrest or delay in the passage of the tablet through the gastrointestinal tract.
  • For the older adult population, use should be with caution due to the greater likelihood of decreased renal function.
  • Safety and effectiveness in pediatric patients have been officially not established by the regulatory authority.

The regulatory profile strictly limits use to the approved adult population managing specified kidney stone conditions and explicitly excludes patient groups with compromised potassium excretion or GI motility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Alkasolve (Potassium Citrate) is defined by its effect on serum potassium and urinary chemistry, as documented in regulatory information.

Contraindicated Combinations Co-administration with potassium-sparing diuretics, such as triamterene, spironolactone, or amiloride, is formally contraindicated due to the high risk of severe hyperkalemia. Anticholinergic medications are also contraindicated because they slow gastrointestinal transit, increasing the potential for localized mucosal damage from the tablet.

Pharmacodynamic Interactions Concomitant use with other agents that can increase potassium levels may enhance the hyperkalemic effect. This interaction pattern is documented with RAAS inhibitors (e.g., ACE inhibitors and ARBs), certain immunosuppressants, and nonsteroidal anti-inflammatory drugs (NSAIDs). The combination with methenamine must be avoided because the urinary alkalinization reduces its antibacterial activity.

Exposure Modification The change in urinary pH caused by Alkasolve modifies the renal excretion of other drugs. This effect increases the renal clearance of weakly acidic medicines (e.g., salicylates) and prolongs the half-life of weakly basic medicines (e.g., quinine), resulting in altered systemic exposure. Furthermore, the citrate component may increase the absorption of co-administered aluminum hydroxide. The risk of interaction-related hyperkalemia is specifically noted to be heightened in patients with renal insufficiency.

Mechanism of Action

Mechanisms of Action (Magnesium Trisilicate)


Chemical pH Buffering and Neutralization

The primary effect initiates through a direct, non-systemic acid-base reaction consuming free Hydrochloric Acid ( HCl) within the stomach lumen. This physicochemical interaction rapidly elevates the local pH level. This immediate neutralization of the gastric environment fundamentally reduces the concentration of HCl acting on chemosensitive neurons, modulating their activation pattern.


️ Physical Gastro-Mucosal Barrier

Following the initial reaction, the compound yields colloidal silica ( SiO2), which precipitates to form a viscous, adherent gel . This physical layer acts as an extrinsic barrier, creating sustained physical separation of the epithelium from luminal contents.


Adsorption of Corrosive Mediators

The resulting silica gel exhibits a high adsorption capacity, physically binding and sequestering aggressive molecules, notably the proteolytic enzyme Pepsin, alongside bile acids. This mechanism lowers the effective concentration of these digestive mediators, contributing to the multifaceted physical and chemical effect profile by reducing the potential for both chemical corrosivity and subsequent enzymatic degradation of the tissue.

Dosage and Administration Information

Administration Scope

Instruction Detail
Route of administration Oral.
Dosing schedule Initial doses are 30 mEq per day for mild hypocitraturia or 60 mEq per day for severe hypocitraturia. The maximum daily dose is 100 mEq per day.
Timing in relation to meals Must be taken with meals or within 30 minutes after meals or a bedtime snack.
Preparation requirements (if applicable) Extended-release tablets must be swallowed whole with sufficient liquid; do not crush, chew, or suck.
Age-group administration rules Safety and effectiveness have not been established in pediatric patients.
Special procedural conditions Requires concurrent maintenance of a high fluid intake (targeting a urine volume ge 2 L/day) and salt limitation.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral.
Frequency pattern Multiple times per day (BID or TID).
Use-context constraints Requires laboratory monitoring (urinary pH and citrate levels) for dose adjustment and maintenance.

Resulting Procedural Structure

Official step sequence:

  • Take the prescribed dose two or three times daily (BID or TID) with or shortly after a full meal or snack.
  • If using the extended-release tablet, swallow it whole to ensure gradual delivery and prevent local irritation.
  • Maintain a high fluid intake and a low salt diet throughout the use of the medicine.
  • Adjustments to the dose are made based on the results of 24-hour urinary chemistry testing.

Connection to the overall use protocol (2–4 sentences): The official instructions establish that the medicine's use is a long-term, titrated regimen strictly defined by specific parameters of urinary chemistry. This requires precise adherence to taking the extended-release tablet without alteration, and scheduling doses consistently with meals multiple times per day. The entire process is structured as a monitored approach where administration conditions, dose frequency, and fluid intake are all essential, interconnected elements.

Recent Clinical Evidence

Research Evidence Overview: Clinical Studies for Alkasolve

Evidence for use in Recurrent Calcium Oxalate Kidney Stones

Alkasolve (potassium citrate) was evaluated in research examining factors related to recurrent kidney stone formation in adults with low urinary citrate levels (hypocitraturia). The research base includes randomized controlled trials (RCTs) and systematic reviews that monitored outcomes such as stone formation rate, urinary pH, and citrate levels over time. While findings describe patterns related to stone event rates, evidence quality varies across studies, and data are limited regarding its specific effect on calcium phosphate stone formation.

Evidence for use in Uric Acid Stone Conditions

Research also examined Alkasolve for conditions associated with uric acid stones (lithiasis). Studies focused on stone dissolution success rates and long-term observational trials. These studies monitored changes in urinary pH and stone clearance. Research contributes to understanding short-term changes; however, comparative evidence is lacking for large-scale prevention trials when focusing specifically on uric acid stone recurrence.

Evidence for use in Renal Tubular Acidosis (RTA)

Alkasolve was evaluated in patients with a specific kidney disorder known as distal RTA who also form calcium stones. Prospective clinical studies monitored stone formation rates, as well as changes in urinary pH and citrate excretion in this specific patient group. Findings describe consistent patterns observed in urinary chemistry. A research limitation frame is that the foundational research often involved sample sizes that were modest, meaning results apply primarily to the specific populations studied.

Long-Term Studies and Follow-Up Data & Research Gaps

Long-term studies explored the maintenance of observed patterns related to stone recurrence, tracking outcomes over several years. Evidence is limited for certain groups; data for pediatric and older adult populations remain insufficient. Furthermore, available data are insufficient to fully characterize the patterns related to calcium phosphate stone formation. These research limitation frames indicate that long-term effects for these populations are not fully established, and research is ongoing to address these data gaps.

Frequently Asked Questions (FAQ)

Common questions about Alkasolve (FAQ)

Q: How quickly should I expect to notice anything after starting Alkasolve?

The official product information states that the antacid component of the medicine is intended for rapid, non-systemic action to offer quick relief from symptoms like heartburn. For the long-term, prescription use, effectiveness is not based on immediate feeling but is monitored and adjusted over time using repeated 24-hour urinary chemistry testing.

Q: Are the side effects of Alkasolve common, or do most people tolerate it well?

Regulatory documents indicate that the most frequently reported side effects are generally mild gastrointestinal disturbances. These commonly noted effects include abdominal discomfort, nausea, vomiting, and loose stools.

Q: What non-prescription drugs should I be careful taking with Alkasolve?

Official product information notes that potential interactions exist with certain over-the-counter drugs. Specifically, the regulatory profile includes warnings regarding nonsteroidal anti-inflammatory drugs (NSAIDs) and products that contain aluminum hydroxide.

Q: Can older adults take Alkasolve without needing a different dosage?

Official guidelines advise caution when the medicine is used in older adults due to the greater likelihood of decreased kidney function. Any dose adjustments are determined individually based on the results of 24-hour urinary chemistry testing, and not based on age alone.

Q: What kind of research was done to get Alkasolve approved?

The research base summarized in regulatory documents includes multiple types of studies supporting the medicine’s approval. These studies include randomized controlled trials (RCTs), prospective clinical studies, and long-term observational trials.

Q: Does taking Alkasolve mean I have to change my diet or avoid certain foods?

Official administration instructions describe the concurrent need for a high fluid intake throughout the day when using the medicine. Regulatory documents also specify a necessary limitation on salt intake as part of the regimen.

Q: Does Alkasolve need to build up in my system to start working?

For its long-term use, Alkasolve is characterized as a maintenance regimen involving clinical monitoring. Effectiveness is typically determined by reaching specific laboratory targets measured through repeated 24-hour urinary chemistry testing, rather than relying on a fixed build-up period.

Q: What are the main reasons someone would have to stop taking Alkasolve?

Official warnings and contraindications define the primary circumstances under which the medicine would be discontinued. This includes the development of serious adverse reactions, such as severe hyperkalemia or gastrointestinal lesions, or the existence of a formal contraindication like severe renal impairment.

Q: How does Alkasolve affect people who have existing heart conditions?

Regulatory safety data advises caution for patients with pre-existing cardiac disease due to their increased susceptibility to the serious effects of hyperkalemia (high potassium levels). Furthermore, severe myocardial damage is listed as a formal contraindication for the medicine's use.

Q: Is there a specific lab test required before starting Alkasolve?

Official instructions establish that the medicine’s use involves specific laboratory monitoring for dose adjustment and maintenance throughout the course of treatment. This monitoring typically involves regular testing of urinary pH and citrate levels.

Q: What does the latest research say about the long-term use of Alkasolve?

Long-term studies have explored patterns related to the maintenance of effects on stone recurrence over several years. Regulatory summaries, however, note that the available data for pediatric and older adult populations remain insufficient to fully characterize the long-term effects for these specific groups.

Q: Why do some people take Alkasolve in the morning and others at night?

The official dosing schedule for the medicine is defined as being taken multiple times per day (BID or TID). The timing is tied directly to food intake, as administration is noted to occur with meals or shortly after a full meal or a bedtime snack.

Q: Is Alkasolve okay for people who have a history of stomach sensitivity?

Official warnings indicate that common side effects include gastrointestinal disturbances such as nausea and abdominal discomfort. Regulatory documents also contraindicate the use of the medicine for conditions like peptic ulcer disease or GI obstruction that delay the tablet's passage.

Q: Is Alkasolve only used for the condition listed in the TV ad?

According to official regulatory documents, the medicine has indications for two distinct purposes. It is officially used for the management of specific kidney stone conditions, and one of its components is also available as an over-the-counter antacid for the symptomatic relief of heartburn and indigestion.

Q: Does Alkasolve contain a pain reliever?

The active ingredients are Magnesium Trisilicate and Potassium Citrate. Regulatory sources classify these components as an Antacid/Adsorbent and a Urinary Alkalinizing Agent, respectively, and not as analgesic or pain-relieving medicines.

Q: What happens if I forget to take Alkasolve one time?

Patient-friendly regulatory information typically provides guidance for missed doses. This guidance generally describes that if a dose is missed, it can be taken as soon as remembered, unless it is already close to the time for the next scheduled dose.

Q: Can Alkasolve cause mood changes or feel like it's making me anxious?

Mood changes, anxiety, or other psychological effects are not listed among the most commonly reported adverse reactions documented in the official regulatory safety documents.

Q: Is it true that Alkasolve can change the way my body processes caffeine?

Official drug interaction information describes that the change in urinary pH caused by the medicine can alter the way the kidneys eliminate certain other drugs. This mechanism is noted to potentially affect substances that are processed as weak bases.

Q: Why do doctors use Alkasolve for a condition that doesn't seem related to its main purpose?

The medicine has two distinct uses recognized in official documents, corresponding to its two components. One part is used for symptomatic relief as an antacid, and the other is prescribed for the long-term management of specific conditions related to kidney stone formation.

Q: Is there a generic version of Alkasolve available?

Regulatory product listings, such as those maintained by the FDA, will specify if an approved generic equivalent is available for public dispensing.

Q: Is it normal to feel a bit tired for the first few days on Alkasolve?

Fatigue or tiredness is not listed among the most commonly reported or serious adverse reactions documented in official regulatory texts regarding the medicine’s safety profile.

Q: If I have a mild headache while on Alkasolve, is it related to the medicine?

Headache is not documented as one of the frequently reported or serious adverse reactions in the official safety profile for the medicine.

Q: Does Alkasolve show up on drug screening tests?

The active ingredients, potassium citrate and magnesium trisilicate, are not typically included in the common drug screening panels used in workplace or law enforcement testing.

Q: Is there a risk of becoming dependent on Alkasolve?

Regulatory agencies do not classify the active ingredients in the medicine as having potential for abuse. Official drug scheduling and product labels indicate no risk of physical dependence is described.

Q: Can Alkasolve affect my sleep, either making me drowsy or keeping me awake?

Central Nervous System (CNS) effects such as drowsiness or insomnia are not listed among the common adverse reactions documented in the regulatory safety profile for this medicine.

Q: Are there any specific warnings about taking Alkasolve before surgery?

Official warnings note the need for caution regarding surgical procedures. This is typically due to the risk of hyperkalemia (high potassium levels), especially if there is a risk of pre- or post-operative changes in kidney function.

Q: I've read about a black box warning; what does that actually mean for Alkasolve?

The term “Boxed Warning” (sometimes called a black box warning) refers to a special section on a regulatory label that highlights a specific serious risk associated with the medicine. If such a warning is present, the official document will precisely describe the risk that it highlights.

Q: Can Alkasolve impact my blood pressure readings?

While blood pressure changes are not listed as a common side effect, the medicine’s official interaction profile notes that it interacts with a class of drugs called RAAS inhibitors. These medicines are commonly used to control blood pressure.

Q: What happens if I stop taking Alkasolve suddenly?

Regulatory documents describe the potential outcomes of stopping treatment, especially for the conditions requiring long-term maintenance. Sudden discontinuation may result in the recurrence of the underlying medical condition being treated.

Q: Is Alkasolve widely available, or is it a specialty drug?

Regulatory listings define the distribution status of the medicine. The drug is available as a widely distributed prescription product for long-term use, while the antacid component is available over-the-counter (OTC).

Q: Does Alkasolve affect birth control pills?

Official drug interaction summaries will state if there is any effect on the metabolism or effectiveness of oral contraceptives. Any potential effect is typically related to the medicine's influence on pH levels within the body.

Q: How does Alkasolve get broken down and leave the body?

Regulatory information factually describes the body’s handling of the active components. For example, the citrate component is metabolized within the body, while the potassium component is primarily excreted through the kidneys.

Q: Can Alkasolve make my skin more sensitive to the sun?

Photosensitivity (increased sensitivity to the sun) or related reactions are not listed among the commonly reported adverse reactions documented in the official safety profile.

Q: Does Alkasolve have a strong taste or smell?

The product description section in regulatory documents factually details the physical characteristics of the dosage form. These documents describe the tablet's appearance, and if the taste or smell were strong or significant, that information is typically noted.

Q: I heard Alkasolve is related to another old drug; is that true?

The regulatory filing for the medicine will contain information regarding its chemical composition and any historical or chemical relationship to previously approved compounds for similar conditions.

Q: What is the difference between an 'adverse reaction' and a 'side effect' for Alkasolve?

According to official consumer-facing medical resources, the term 'side effect' is often used generally to describe any known undesirable effect of a drug. 'Adverse reaction' is the official term for a specific, documented negative event identified in regulatory documents.

Q: Does Alkasolve have any known interactions with grapefruit juice?

Regulatory documents detail food and beverage interactions only if they significantly affect the drug’s metabolism or absorption. If a significant interaction with grapefruit juice were officially known, it would be noted in the food interaction section.

Q: Will Alkasolve interfere with my ability to drive or operate machinery?

Official regulatory information includes an explicit statement regarding the medicine's known impact on psychomotor function. This information helps clarify whether any effects that could interfere with driving or operating machinery have been observed.

Q: Is it possible to be allergic to the ingredients in Alkasolve?

Official regulatory documents list hypersensitivity, or an allergy, to the active or inactive ingredients of the medicine as a formal contraindication for use.

Q: How long does it take for Alkasolve to be completely cleared from my body?

The regulatory label describes the drug’s elimination process, providing factual data such as the elimination half-life or the time required for the major clearance of the active components from the body.

Q: Can Alkasolve affect my appetite, making me hungrier or less hungry?

Changes in appetite, either making a person hungrier or less hungry, are not listed among the most commonly reported adverse reactions documented in the official safety profile.

Q: I heard Alkasolve can affect my hair/nails; is this true?

Dermatological or appendage effects, such as those related to hair or nails, are not listed among the commonly reported adverse reactions documented in the official safety profile.

Q: Does Alkasolve have any effect on my cholesterol levels?

Cholesterol or lipid effects are not listed among the reported side effects. Furthermore, official administration instructions do not specify the monitoring of cholesterol levels as a standard clinical chemistry parameter for use of the medicine.

How should Alkasolve be stored and disposed of?

How to Store and Dispose of Alkasolve: Official Regulatory Information

Official regulatory documents define strict rules for storing and disposing of Alkasolve to maintain its stability and prevent contamination.

Requirement Area Official Instructions
Temperature & Environment Store at Controlled Room Temperature (20 C to 25 C). Do not freeze or expose to temperatures above 30 C.
Container & Handling Keep in the original, tightly closed container. Protect the medicine from light and moisture.
Child Protection Keep Alkasolve strictly out of the sight and reach of children.
Disposal Protocol Dispose of unused or expired product through an authorized drug take-back program. Do not flush Alkasolve down the toilet or pour it into a drain.
Stability Stability may be time-limited after the container is first opened or reconstituted; discard any remaining product after the documented period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alkasolve found in:

A-Z Index: